Acurx Pharmaceuticals Inc Ordinary Shares ACXP
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ACXP is a good fit for your portfolio.
News
-
USPTO Grants Acurx Pharmaceuticals New Patent for Ibezapolstat to Treat CDI While Reducing Recurrence of Infection and Improving Health of the Gut Microbiome
-
Acurx Pharmaceuticals, Inc. to Discuss Second Quarter 2024 Financial Results on August 9, 2024 Conference Call and Provide Business Update
-
Acurx Pharmaceuticals Announces Presentation of Ibezapolstat Phase 2 Clinical Trial Results for CDI at Scientific Conference
-
New to The Street Announces Episode 576, Four Business Guest Interviews, Airs on Bloomberg TV as Sponsored Programming, Tonight, Thursday, June 6, 2024, at 9:30 PM PT
-
Acurx Announces Successful FDA End-of-Phase 2 Meeting and Phase 3 Readiness for Ibezapolstat in the Treatment of C. difficile Infection
-
Acurx Pharmaceuticals, Inc. Reports First Quarter 2024 Results and Provides Business Update
-
Acurx Pharmaceuticals Announces Presentation of Ibezapolstat Phase 2 Clinical Trial Results at ESCMID Global 2024 Scientific Conference
Trading Information
- Previous Close Price
- $2.26
- Day Range
- $2.26–2.40
- 52-Week Range
- $1.17–8.82
- Bid/Ask
- $2.22 / $2.33
- Market Cap
- $36.12 Mil
- Volume/Avg
- 14,401 / 59,745
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 4
- Website
- https://www.acurxpharma.com
Valuation
Metric
|
ACXP
|
---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 6.09 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
Metric
|
ACXP
|
---|---|
Quick Ratio | 2.87 |
Current Ratio | 2.93 |
Interest Coverage | — |
Quick Ratio
ACXP
Profitability
Metric
|
ACXP
|
---|---|
Return on Assets (Normalized) | −147.62% |
Return on Equity (Normalized) | −229.37% |
Return on Invested Capital (Normalized) | −229.37% |
Return on Assets
ACXP
Biotechnology Industry Comparables
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|---|
Novo Nordisk A/S ADR
NVO
| Wqwzccszn | Xnlg | $570.2 Bil | |||
Vertex Pharmaceuticals Inc
VRTX
| Vwnxjzgh | Hfsnkt | $127.0 Bil | |||
Regeneron Pharmaceuticals Inc
REGN
| Zydtltrvz | Flnrjkf | $117.3 Bil | |||
Moderna Inc
MRNA
| Gwmbhgs | Dzwds | $46.1 Bil | |||
Alnylam Pharmaceuticals Inc
ALNY
| Rkxwdlk | Mlqqddz | $30.1 Bil | |||
argenx SE ADR
ARGX
| Ftywhzhl | Wmtw | $28.8 Bil | |||
BioNTech SE ADR
BNTX
| Jcxkcslgy | Frvl | $20.7 Bil | |||
Biomarin Pharmaceutical Inc
BMRN
| Fkjpvmrh | Fsxtlvp | $16.3 Bil | |||
United Therapeutics Corp
UTHR
| Ykfwljzb | Nbrw | $14.9 Bil | |||
Incyte Corp
INCY
| Mbsrslmlc | Wwzyjr | $13.5 Bil |